Nevirapine Wockhardt Uk (Nevirapine)

Nevirapine binds to a hydrophobic pocket on the HIV-1 reverse transcriptase enzyme, causing a conformational change that blocks both RNA‑dependent and DNA‑dependent DNA polymerase activities. This inhibition prevents the synthesis of viral DNA, halting replication of the virus within host cells.

The dosage of nevirapine is individualized by the prescribing clinician based on factors such as patient weight, treatment history, and co‑administered medications. The prescriber determines the appropriate regimen and any necessary dose adjustments.

Nevirapine falls under an unknown pregnancy category, and safety data are limited. Use during pregnancy or lactation should be considered only when the potential benefits outweigh the possible risks to the fetus or infant, and it should be managed by a specialist experienced in HIV care.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nevirapine, an NNRTI, differs from protease inhibitors and integrase inhibitors in its mechanism of binding directly to reverse transcriptase. Compared with efavirenz, another NNRTI, nevirapine has a lower incidence of central nervous system side effects but a higher risk of skin and hepatic reactions, influencing regimen selection based on patient tolerance.

Nevirapine tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in humid or excessively hot environments, and keep out of reach of children.

Nevirapine is administered orally as a tablet. It can be taken with or without food, although taking it with a light meal may reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, hepatic failure, hypersensitivity syndrome, neutropenia, and anaphylaxis. Patients should be instructed to seek immediate medical attention if they develop a rash covering large areas, jaundice, unexplained fatigue, or signs of an allergic reaction.

Nevirapine should be avoided in patients with a history of severe hepatic impairment, pre-existing severe skin reactions to NNRTIs, known hypersensitivity to nevirapine, or concurrent use of contraindicated drugs that markedly increase its plasma levels. Clinicians must assess individual risk before initiating therapy.